نتائج البحث

| group1 = [[Antiarrhythmic agent#Class I agents|class I]]<BR>([[sodium channel blocker|Na⁺ channel blockers]]) | group3 = [[Antiarrhythmic agent#Class III agents|class III]]<BR>([[Cardiac action potential#Phase 3|Phase 3]]→, [[potassiu

...de C|drug]] ([[Template:Cardiac glycosides|C1A]]/[[Template:Antiarrhythmic agents|1B]]/[[Template:Cardiac stimulants excluding cardiac glycosides|1C]]/[[Temp

*Template:Acne agents أدوية حب الشباب - موجود أضيف الرابط

...e book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | pa ...rnal | author = Yoshidomi M, Sukamoto T, Morita T, Ito K, Nose T | title = Antiarrhythmic effect of KB-944, a new calcium antagonist. A comparison with verapamil and

...inflammatory medicines, medicines used to treat gout and disease modifying agents in rheumatoid disorders== ===Disease modifying agents used in rheumatoid disorders (DMARDs)===

...lus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=1474169 Classifying antiarrhythmic actions: by facts or speculation. Vaughan Williams EM, J Clin Pharmacol. 1 ...irc.ahajournals.org/cgi/content/abstract/81/2/686 Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dan